Critical care explorationsPub Date : 2024-10-11eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001163
Bruno Garcia, Benoit Ter Schiphorst, Fuhong Su, Adrien Picod, Theo Ikenna-Uba, Raphaël Favory, Filippo Annoni, Alexandre Mebazaa, Jean-Louis Vincent, Jacques Creteur, Fabio S Taccone, Antoine Herpain
{"title":"Alterations in the Renin-Angiotensin System in Experimental Septic Shock.","authors":"Bruno Garcia, Benoit Ter Schiphorst, Fuhong Su, Adrien Picod, Theo Ikenna-Uba, Raphaël Favory, Filippo Annoni, Alexandre Mebazaa, Jean-Louis Vincent, Jacques Creteur, Fabio S Taccone, Antoine Herpain","doi":"10.1097/CCE.0000000000001163","DOIUrl":"https://doi.org/10.1097/CCE.0000000000001163","url":null,"abstract":"<p><strong>Objectives: </strong>To analyze dynamic changes in the renin-angiotensin system (RAS) during septic shock, focusing on angiotensin-converting enzyme (ACE) activity and the balance between angiotensin peptides, using a mass spectrometry method.</p><p><strong>Design: </strong>Experimental septic shock model induced by peritonitis in swine.</p><p><strong>Setting: </strong>Experimental Laboratory, Department of Intensive Care, Erasme Hospital, Université Libre de Bruxelles.</p><p><strong>Subjects: </strong>Forty time points from eight mechanically ventilated pigs.</p><p><strong>Interventions: </strong>Septic shock was induced using intraperitoneal instillation of autologous feces, followed by standardized fluid resuscitation, norepinephrine infusion, antibiotic administration, and peritoneal lavage.</p><p><strong>Measurements and main results: </strong>The induction of sepsis resulted in a significant increase in plasma renin activity and levels of angiotensin I and II, with a significant decrease in ACE activity observed from 4 hours post-resuscitation and a notable rise in the angiotensin I/angiotensin II ratio at 12 hours. Additionally, a shift toward the angiotensin-(1-7) axis was observed, evidenced by an increased angiotensin-(1-7)/angiotensin II ratio.</p><p><strong>Conclusions: </strong>The study highlighted dynamic shifts in the RAS during septic shock, characterized by reduced circulating ACE activity, elevated angiotensin I/II ratio, and a shift toward the angiotensin-(1-7) axis. These findings suggest an adaptive response within the RAS, potentially offering new insights into sepsis management and therapeutic targets.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473057/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142483246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-10-11eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001165
Kevin G Buell, Kyle A Carey, Nicole Dussault, William F Parker, Jay Dumanian, Sivasubramanium V Bhavani, Emily R Gilbert, Christopher J Winslow, Nirav S Shah, Majid Afshar, Dana P Edelson, Matthew M Churpek
{"title":"Development and Validation of a Machine Learning Model for Early Detection of Untreated Infection.","authors":"Kevin G Buell, Kyle A Carey, Nicole Dussault, William F Parker, Jay Dumanian, Sivasubramanium V Bhavani, Emily R Gilbert, Christopher J Winslow, Nirav S Shah, Majid Afshar, Dana P Edelson, Matthew M Churpek","doi":"10.1097/CCE.0000000000001165","DOIUrl":"10.1097/CCE.0000000000001165","url":null,"abstract":"<p><strong>Background: </strong>Early diagnostic uncertainty for infection causes delays in antibiotic administration in infected patients and unnecessary antibiotic administration in noninfected patients.</p><p><strong>Objective: </strong>To develop a machine learning model for the early detection of untreated infection (eDENTIFI), with the presence of infection determined by clinician chart review.</p><p><strong>Derivation cohort: </strong>Three thousand three hundred fifty-seven adult patients hospitalized between 2006 and 2018 at two health systems in Illinois, United States.</p><p><strong>Validation cohort: </strong>We validated in 1632 patients in a third Illinois health system using area under the receiver operating characteristic curve (AUC).</p><p><strong>Prediction model: </strong>Using a longitudinal discrete-time format, we trained a gradient boosted machine model to predict untreated infection in the next 6 hours using routinely available patient demographics, vital signs, and laboratory results.</p><p><strong>Results: </strong>eDENTIFI had an AUC of 0.80 (95% CI, 0.79-0.81) in the validation cohort and outperformed the systemic inflammatory response syndrome criteria with an AUC of 0.64 (95% CI, 0.64-0.65; p < 0.001). The most important features were body mass index, age, temperature, and heart rate. Using a threshold with a 47.6% sensitivity, eDENTIFI detected infection a median 2.0 hours (interquartile range, 0.9-5.2 hr) before antimicrobial administration, with a negative predictive value of 93.6%. Antibiotic administration guided by eDENTIFI could have decreased unnecessary IV antibiotic administration in noninfected patients by 10.8% absolute or 46.4% relative percentage points compared with clinicians.</p><p><strong>Conclusion: </strong>eDENTIFI could both decrease the time to antimicrobial administration in infected patients and unnecessary antibiotic administration in noninfected patients. Further prospective validation is needed.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11473064/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142402357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-10-04eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001125
Jocelyn R Grunwell, Min Huang, Susan T Stephenson, Mallory Tidwell, Michael J Ripple, Anne M Fitzpatrick, Rishikesan Kamaleswaran
{"title":"RNA Sequencing Analysis of Monocytes Exposed to Airway Fluid From Children With Pediatric Acute Respiratory Distress Syndrome.","authors":"Jocelyn R Grunwell, Min Huang, Susan T Stephenson, Mallory Tidwell, Michael J Ripple, Anne M Fitzpatrick, Rishikesan Kamaleswaran","doi":"10.1097/CCE.0000000000001125","DOIUrl":"10.1097/CCE.0000000000001125","url":null,"abstract":"<p><strong>Objectives: </strong>Monocytes are plastic cells that assume different polarization states that can either promote inflammation or tissue repair and inflammation resolution. Polarized monocytes are partially defined by their transcriptional profiles that are influenced by environmental stimuli. The airway monocyte response in pediatric acute respiratory distress syndrome (PARDS) is undefined. To identify differentially expressed genes and networks using a novel transcriptomic reporter assay with donor monocytes exposed to the airway fluid of intubated children with and at-risk for PARDS. To determine differences in gene expression at two time points using the donor monocyte assay exposed to airway fluid from intubated children with PARDS obtained 48-96 hours following initial tracheal aspirate sampling.</p><p><strong>Design: </strong>In vitro pilot study carried out using airway fluid supernatant.</p><p><strong>Setting: </strong>Academic 40-bed PICU.</p><p><strong>Participants: </strong>Fifty-seven children: 44 children with PARDS and 13 children at-risk for PARDS.</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>We performed bulk RNA sequencing using a transcriptomic reporter assay of monocytes exposed to airway fluid from intubated children to discover gene networks differentiating PARDS from at-risk for PARDS and those differentiating mild/moderate from severe PARDS. We also report differences in gene expression in children with PARDS 48-96 hours following initial tracheal aspirate sampling. We found that interleukin (IL)-10, IL-4, and IL-13, cytokine/chemokine signaling, and the senescence-associated secretory phenotype are upregulated in monocytes exposed to airway fluid from intubated children with PARDS compared with those at-risk for PARDS. Signaling by NOTCH, histone deacetylation/acetylation, DNA methylation, chromatin modifications (B-WICH complex), and RNA polymerase I transcription and its associated regulatory apparatus were upregulated in children with PARDS 48-96 hours following initial tracheal aspirate sampling.</p><p><strong>Conclusions: </strong>We identified gene networks important to the PARDS airway immune response using bulk RNA sequencing from a monocyte reporter assay that exposed monocytes to airway fluid from intubated children with and at-risk for PARDS. Mechanistic investigations are needed to validate our findings.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11458172/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-10-03eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001162
Brian Murray, Janhavi Athale, Robert A Balk, Michael L Behal, Judah E Brown, Tyler Chanas, Roxana Dumitru, Dalton C Gifford, Benjamin Hohlfelder, Honey M Jones, Mary Beth F Makic, Michelle S Rausen, Alicia J Sacco, Benjamin J Sines, Payal K Gurnani
{"title":"Major Publications in the Critical Care Pharmacotherapy Literature: 2023.","authors":"Brian Murray, Janhavi Athale, Robert A Balk, Michael L Behal, Judah E Brown, Tyler Chanas, Roxana Dumitru, Dalton C Gifford, Benjamin Hohlfelder, Honey M Jones, Mary Beth F Makic, Michelle S Rausen, Alicia J Sacco, Benjamin J Sines, Payal K Gurnani","doi":"10.1097/CCE.0000000000001162","DOIUrl":"10.1097/CCE.0000000000001162","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023.</p><p><strong>Data sources: </strong>PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update.</p><p><strong>Study selection: </strong>Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article.</p><p><strong>Data extraction: </strong>Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature.</p><p><strong>Data synthesis: </strong>The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion.</p><p><strong>Conclusions: </strong>This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11452093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Matthew M Churpek, Ryan Ingebritsen, Kyle A Carey, Saieesh A Rao, Emily Murnin, Tonela Qyli, Madeline K Oguss, Jamila Picart, Leena Penumalee, Benjamin D Follman, Lily K Nezirova, Sean T Tully, Charis Benjamin, Christopher Nye, Emily R Gilbert, Nirav S Shah, Christopher J Winslow, Majid Afshar, Dana P Edelson
{"title":"Causes, Diagnostic Testing, and Treatments Related to Clinical Deterioration Events Among High-Risk Ward Patients.","authors":"Matthew M Churpek, Ryan Ingebritsen, Kyle A Carey, Saieesh A Rao, Emily Murnin, Tonela Qyli, Madeline K Oguss, Jamila Picart, Leena Penumalee, Benjamin D Follman, Lily K Nezirova, Sean T Tully, Charis Benjamin, Christopher Nye, Emily R Gilbert, Nirav S Shah, Christopher J Winslow, Majid Afshar, Dana P Edelson","doi":"10.1097/CCE.0000000000001161","DOIUrl":"10.1097/CCE.0000000000001161","url":null,"abstract":"<p><strong>Importance: </strong>Timely intervention for clinically deteriorating ward patients requires that care teams accurately diagnose and treat their underlying medical conditions. However, the most common diagnoses leading to deterioration and the relevant therapies provided are poorly characterized.</p><p><strong>Objectives: </strong>We aimed to determine the diagnoses responsible for clinical deterioration, the relevant diagnostic tests ordered, and the treatments administered among high-risk ward patients using manual chart review.</p><p><strong>Design, setting, and participants: </strong>This was a multicenter retrospective observational study in inpatient medical-surgical wards at four health systems from 2006 to 2020. Randomly selected patients (1000 from each health system) with clinical deterioration, defined by reaching the 95th percentile of a validated early warning score, electronic Cardiac Arrest Risk Triage, were included.</p><p><strong>Main outcomes and measures: </strong>Clinical deterioration was confirmed by a trained reviewer or marked as a false alarm if no deterioration occurred for each patient. For true deterioration events, the condition causing deterioration, relevant diagnostic tests ordered, and treatments provided were collected.</p><p><strong>Results: </strong>Of the 4000 included patients, 2484 (62%) had clinical deterioration confirmed by chart review. Sepsis was the most common cause of deterioration (41%; n = 1021), followed by arrhythmia (19%; n = 473), while liver failure had the highest in-hospital mortality (41%). The most common diagnostic tests ordered were complete blood counts (47% of events), followed by chest radiographs (42%) and cultures (40%), while the most common medication orders were antimicrobials (46%), followed by fluid boluses (34%) and antiarrhythmics (19%).</p><p><strong>Conclusions and relevance: </strong>We found that sepsis was the most common cause of deterioration, while liver failure had the highest mortality. Complete blood counts and chest radiographs were the most common diagnostic tests ordered, and antimicrobials and fluid boluses were the most common medication interventions. These results provide important insights for clinical decision-making at the bedside, training of rapid response teams, and the development of institutional treatment pathways for clinical deterioration.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446591/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Dawoon Jung, Omayma A Kishk, Adnan T Bhutta, Ginny E Cummings, Hana M El Sahly, Manpreet K Virk, Brady S Moffett, Jennifer L Morris Daniel, Amy Watanabe, Nicholas Fishbane, Karen L Kotloff, Kenan Gu, Varduhi Ghazaryan, Jogarao V S Gobburu, Ayse Akcan-Arikan, James D Campbell
{"title":"Evaluation of Vancomycin Dose Needed to Achieve 24-Hour Area Under the Concentration-Time Curve to Minimum Inhibitory Concentration Ratio Greater Than or Equal to 400 Using Pharmacometric Approaches in Pediatric Intensive Care Patients.","authors":"Dawoon Jung, Omayma A Kishk, Adnan T Bhutta, Ginny E Cummings, Hana M El Sahly, Manpreet K Virk, Brady S Moffett, Jennifer L Morris Daniel, Amy Watanabe, Nicholas Fishbane, Karen L Kotloff, Kenan Gu, Varduhi Ghazaryan, Jogarao V S Gobburu, Ayse Akcan-Arikan, James D Campbell","doi":"10.1097/CCE.0000000000001159","DOIUrl":"10.1097/CCE.0000000000001159","url":null,"abstract":"<p><strong>Objectives: </strong>To investigate which independent factor(s) have an impact on the pharmacokinetics of vancomycin in critically ill children, develop an equation to predict the 24-hour area under the concentration-time curve from a trough concentration, and evaluate dosing regimens likely to achieve a 24-hour area under the concentration-time curve to minimum inhibitory concentration ratio (AUC24/MIC) greater than or equal to 400.</p><p><strong>Design: </strong>Prospective population pharmacokinetic study of vancomycin.</p><p><strong>Setting: </strong>Critically ill patients in quaternary care PICUs.</p><p><strong>Patients: </strong>Children 90 days old or older to younger than 18 years who received IV vancomycin treatment, irrespective of the indication for use, in the ICUs at the University of Maryland Children's Hospital and Texas Children's Hospital were enrolled.</p><p><strong>Interventions: </strong>Vancomycin was prescribed at doses and intervals chosen by the treating clinicians.</p><p><strong>Measurements and main results: </strong>A median of four serum levels of vancomycin per patient were collected along with other variables for up to 7 days following the first administration. These data were used to characterize vancomycin pharmacokinetics and evaluate the factors affecting the variability in achieving AUC24/MIC ratio greater than or equal to 400 in PICU patients who are not on extracorporeal therapy. A total of 302 children with a median age of 6.0 years were enrolled. A two-compartment model described the pharmacokinetics of vancomycin with the clearance of 2.76 L/hr for a typical patient weighing 20 kg. The glomerular filtration rate estimated using either the bedside Schwartz equation or the chronic kidney disease in children equation was the only statistically significant predictor of clearance among the variables evaluated, exhibiting equal predictive performance. The trough levels achieving AUC24/MIC = 400 were 5.6-10.0 μg/mL when MIC = 1 μg/mL. The target of AUC24/MIC greater than or equal to 400 was achieved in 60.4% and 36.5% with the typical dosing regimens of 15 mg/kg every 6 and 8 hours (q6h and q8h), respectively.</p><p><strong>Conclusions: </strong>The pharmacokinetics of vancomycin in critically ill children were dependent on the estimated glomerular filtration rate only. Trough concentrations accurately predict AUC24. Typical pediatric vancomycin dosing regimens of 15 mg/kg q6h and q8h will often lead to AUC24/MIC under 400.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446596/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-09-25eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001155
William Miller, Jacob Braaten, Anna Rauzi, Jillian Wothe, Kristiana Sather, Angela Phillips, Danika Evans, Ramiro Saavedra-Romero, Matthew Prekker, Melissa E Brunsvold
{"title":"Thromboembolic Complications in Continuous Versus Interrupted Anticoagulation During Venovenous Extracorporeal Membrane Oxygenation: A Multicenter Study.","authors":"William Miller, Jacob Braaten, Anna Rauzi, Jillian Wothe, Kristiana Sather, Angela Phillips, Danika Evans, Ramiro Saavedra-Romero, Matthew Prekker, Melissa E Brunsvold","doi":"10.1097/CCE.0000000000001155","DOIUrl":"https://doi.org/10.1097/CCE.0000000000001155","url":null,"abstract":"<p><strong>Objectives: </strong>Continuous, therapeutic anticoagulation is the standard of care for patients on extracorporeal membrane oxygenation (ECMO). The risks of hemorrhage exacerbated by anticoagulation must be weighed with the thrombotic risks associated with ECMO. We hypothesized increased thrombotic events in patients who had interrupted (vs. continuous) anticoagulation during venovenous ECMO.</p><p><strong>Design: </strong>This is a retrospective, observational study.</p><p><strong>Setting: </strong>Enrollment of individuals took place at three adult ECMO centers in Minnesota from 2013 to 2022.</p><p><strong>Patients: </strong>This study consists of 346 patients supported with venovenous ECMO.</p><p><strong>Interventions: </strong>Anticoagulation administration was collected from electronic health records, including frequency and duration of anticoagulation interruptions (IAs) and timing and type of thrombotic events, and data were analyzed using descriptive statistics.</p><p><strong>Measurements and main results: </strong>A total of 156 patients had IA during their ECMO run and 190 had continuous anticoagulation. Risk adjusted logistic regression demonstrated that individuals in the IA group were not statistically more likely to experience a thrombotic complication (odds ratio [OR], 0.69; 95% CI, 0.27-1.70) or require ECMO circuit change (OR, 1.36; 95% CI, 0.52-3.49). Subgroup analysis demonstrated greater frequency of overall thrombotic events with increasing frequency and duration of anticoagulation being interrupted (p = 0.001).</p><p><strong>Conclusions: </strong>Our multicenter analysis found a similar frequency of thrombotic events in patients on ECMO when anticoagulation was interrupted vs. administered continuously. Further investigation into the impact of the frequency and duration of these interruptions is warranted.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427029/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334448","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-09-25eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001160
Federico Angriman, Shaurya Taran, Natalia Angeloni, Catherine Devion, Jong Woo Lee, Neill K J Adhikari
{"title":"Antiseizure Medications in Adult Patients With Traumatic Brain Injury: A Systematic Review and Bayesian Network Meta-Analysis.","authors":"Federico Angriman, Shaurya Taran, Natalia Angeloni, Catherine Devion, Jong Woo Lee, Neill K J Adhikari","doi":"10.1097/CCE.0000000000001160","DOIUrl":"10.1097/CCE.0000000000001160","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to evaluate the effectiveness of any antiseizure medication on the incidence of early post-traumatic seizures among adult patients with traumatic brain injury.</p><p><strong>Data sources: </strong>MEDLINE, Embase, PubMed, Cochrane Central Register of Controlled Trials, and LILACS were searched from inception to October 2023.</p><p><strong>Study selection: </strong>We included randomized trials of adult patients with traumatic brain injury evaluating any antiseizure medication compared with either placebo or another agent.</p><p><strong>Data extraction: </strong>Two reviewers independently extracted individual study data and evaluated studies for risk of bias using the Cochrane Risk of Bias tool. Our main outcome of interest was the occurrence of early seizures (i.e., within 7 d); secondary outcomes included late-seizures and all-cause mortality.</p><p><strong>Data synthesis: </strong>Bayesian network meta-analyses were used to derive risk ratios (RRs) alongside 95% credible intervals (CrIs). We used Grading of Recommendations Assessment, Development, and Evaluation methodology to rate the certainty in our findings. Overall, ten individual randomized controlled trials (1851 participants) were included. Compared with placebo, phenytoin (RR, 0.28; 95% CrI, 0.13-0.57; moderate certainty) and levetiracetam (RR, 0.20; 95% CrI, 0.07-0.60; moderate certainty) were associated with a reduction in the risk of early seizures. Carbamazepine may be associated with a reduced risk of early seizures, but the evidence is very uncertain (RR, 0.41; 95% CrI, 0.12-1.27; very low certainty). Valproic acid may result in little to no difference in the risk of early seizures, but the evidence is very uncertain (RR, 0.97; 95% CrI, 0.16-9.00; very low certainty). The evidence is very uncertain about the impact of any antiseizure medication on the risk of late seizures or all-cause mortality at longest reported follow-up time.</p><p><strong>Conclusions: </strong>Phenytoin or levetiracetam reduce the risk of early seizures among adult patients with traumatic brain injury. Further research is needed to evaluate required duration of therapy and long-term safety profiles.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427032/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-09-20eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001156
Denise C Hasson, Katja M Gist, JangDong Seo, Erin K Stenson, Aaron Kessel, Taiki Haga, Sara LaFever, Maria Jose Santiago, Matthew Barhight, David Selewski, Zaccaria Ricci, Nicholas J Ollberding, Natalja L Stanski
{"title":"The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy.","authors":"Denise C Hasson, Katja M Gist, JangDong Seo, Erin K Stenson, Aaron Kessel, Taiki Haga, Sara LaFever, Maria Jose Santiago, Matthew Barhight, David Selewski, Zaccaria Ricci, Nicholas J Ollberding, Natalja L Stanski","doi":"10.1097/CCE.0000000000001156","DOIUrl":"10.1097/CCE.0000000000001156","url":null,"abstract":"<p><strong>Objectives: </strong>Continuous renal replacement therapy (CRRT) and shock are both associated with high morbidity and mortality in the ICU. Adult data suggest renoprotective effects of vasopressin vs. catecholamines (norepinephrine and epinephrine). We aimed to determine whether vasopressin use during CRRT was associated with improved kidney outcomes in children and young adults.</p><p><strong>Design: </strong>Secondary analysis of Worldwide Exploration of Renal Replacement Outcomes Collaborative in Kidney Disease (WE-ROCK), a multicenter, retrospective cohort study.</p><p><strong>Setting: </strong>Neonatal, cardiac, PICUs at 34 centers internationally from January 1, 2015, to December 31, 2021.</p><p><strong>Patients/subjects: </strong>Patients younger than 25 years receiving CRRT for acute kidney injury and/or fluid overload and requiring vasopressors. Patients receiving vasopressin were compared with patients receiving only norepinephrine/epinephrine. The impact of timing of vasopressin relative to CRRT start was assessed by categorizing patients as: early (on or before day 0), intermediate (days 1-2), and late (days 3-7).</p><p><strong>Interventions: </strong>None.</p><p><strong>Measurements and main results: </strong>Of 1016 patients, 665 (65%) required vasopressors in the first week of CRRT. Of 665, 248 (37%) received vasopressin, 473 (71%) experienced Major Adverse Kidney Events at 90 days (MAKE-90) (death, renal replacement therapy dependence, and/or > 125% increase in serum creatinine from baseline 90 days from CRRT initiation), and 195 (29%) liberated from CRRT on the first attempt within 28 days. Receipt of vasopressin was associated with higher odds of MAKE-90 (adjusted odds ratio [aOR], 1.80; 95% CI, 1.20-2.71; <i>p</i> = 0.005) but not liberation success. In the vasopressin group, intermediate/late initiation was associated with higher odds of MAKE-90 (aOR, 2.67; 95% CI, 1.17-6.11; <i>p</i> = 0.02) compared with early initiation.</p><p><strong>Conclusions: </strong>Nearly two-thirds of children and young adults receiving CRRT required vasopressors, including over one-third who received vasopressin. Receipt of vasopressin was associated with more MAKE-90, although earlier initiation in those who received it appears beneficial. Prospective studies are needed to understand the appropriate timing, dose, and subpopulation for use of vasopressin.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419489/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142334447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Critical care explorationsPub Date : 2024-09-20eCollection Date: 2024-10-01DOI: 10.1097/CCE.0000000000001152
Ziming Chen, Michael O Harhay, Eddy Fan, Anders Granholm, Daniel F McAuley, Martin Urner, Christopher J Yarnell, Ewan C Goligher, Anna Heath
{"title":"Statistical Power and Performance of Strategies to Analyze Composites of Survival and Duration of Ventilation in Clinical Trials.","authors":"Ziming Chen, Michael O Harhay, Eddy Fan, Anders Granholm, Daniel F McAuley, Martin Urner, Christopher J Yarnell, Ewan C Goligher, Anna Heath","doi":"10.1097/CCE.0000000000001152","DOIUrl":"10.1097/CCE.0000000000001152","url":null,"abstract":"<p><strong>Background: </strong>Patients with acute hypoxemic respiratory failure are at high risk of death and prolonged time on the ventilator. Interventions often aim to reduce both mortality and time on the ventilator. Many methods have been proposed for analyzing these endpoints as a single composite outcome (days alive and free of ventilation), but it is unclear which analytical method provides the best performance. Thus, we aimed to determine the analysis method with the highest statistical power for use in clinical trials.</p><p><strong>Methods: </strong>Using statistical simulation, we compared multiple methods for analyzing days alive and free of ventilation: the t, Wilcoxon rank-sum, and Kryger Jensen and Lange tests, as well as the proportional odds, hurdle-Poisson, and competing risk models. We compared 14 scenarios relating to: 1) varying baseline distributions of mortality and duration of ventilation, which were based on data from a registry of patients with acute hypoxemic respiratory failure and 2) the varying effects of treatment on mortality and duration of ventilation.</p><p><strong>Results and conclusions: </strong>All methods have good control of type 1 error rates (i.e., avoid false positive findings). When data are simulated using a proportional odds model, the t test and ordinal models have the highest relative power (92% and 90%, respectively), followed by competing risk models. When the data are simulated using survival models, the competing risk models have the highest power (100% and 92%), followed by the t test and a ten-category ordinal model. All models struggled to detect the effect of the intervention when the treatment only affected one of mortality and duration of ventilation. Overall, the best performing analytical strategy depends on the respective effects of treatment on survival and duration of ventilation and the underlying distribution of the outcomes. The evaluated models each provide a different interpretation for the treatment effect, which must be considered alongside the statistical power when selecting analysis models.</p>","PeriodicalId":93957,"journal":{"name":"Critical care explorations","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11419436/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142303479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}